Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT05375461Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of culmerciclib in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2022; status: completed.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05375461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375461.